This dataset contains a mixture of categorical clinical parameters (clinical symptoms, disease severity) and numerical immunological parameters (immunoglobin, T cells, memory B cells, antibodies) taken over a period of 6 months, denoted by timepoint and days post onset of symptoms, along with basic demographics (age, sex) for each donor.
For more details about each variable, see the variable legendfor this dataset
Figure 1. Clinical study overview (Tomic, A et al. NatComm, 2022)
Clinical Parameters
These variables consist of clinical symptoms most commonly associated with SARS-CoV-2 infection, along with the severity of disease experienced by the donors
📋Clinical Symptoms
Common symptoms for SARS-CoV-2 infection:
Fever
Cough
Change or loss of taste
Anosmia : Complete loss of sense of smell
Fatigue
Shortness of breath
Nasal congestion
Sore throat
Myalgia : Muscle pain or soreness
Arthralgia : Joint pain
Headache
Diarrhoea
Vomiting
Nausea
Chest pain
Anorexia : Excessive weight loss
Asthma
😷Disease Severity
Asymptomatic: Donor presents on symptoms while infected
Mild: Donor presents with moderate symptoms upon infection
Severe: Donor presents with more extreme symptoms upon infection
Immunological Parameters
These variables comprise of various immunological assays that quantify immune parameters such as T cells, memory B cells, antibodies and associated processes to obtain a comprehensive view of the cellular and humoral adaptive immune responses.
🛡️Antibodies
Pseudo-Neutralisating Antibodies (pseudoNA Abs): Concentration of neutralizing antibodies to inhibit infection by a SARS-CoV-2 pseudovirus determines efficacy of the donor's antibodies
Antibody-Dependent Effector Functions: Effector functions such as monocyte phagocytosis (ADMP) and NK cell activation (ADNKA) give insight to how antibodies are neutralizing the virus
Immunoglobin Assays: Provides measurements of antibodies specific to SARS-CoV-2 proteins both in the mucous membranes (S-IgA) and circulating in the blood (N-IgG, S-IgG )
Meso Scale Discovery (MSD) Assays: Gives insight to whether the donor's antibodies provide protection against various coronavirus strains (e.g. 229e, NL63) and other respiratory viruses (e.g. MERS)
🦠T cells
SARS-CoV-2 protein-specific T cell responses: Conveys proteins of the SARS-CoV-2 virus the T cells of the donor reacts to most by measuring concentration of T cells specifically responding to each protein (e.g. ORF3, nsp3b, S1)
T cell proliferative responses: Provides insight into which SARS-CoV-2 proteins are most targeted by the CD4 and CD8 cells by measuring their proliferation for each protein
🧪B cells
Spike-specific IgG+ Memory B cells: Concentration of memory B cells specific to seasonal coronavirus stains gives insight to the durable immunity the body has to the various viruses
Responder Status
The seropositivity of the donors at 6 months post symptoms onset determined whether the donor was a low or high responder. This seropositivity was calculated by the titer of the anti-nucleocapsid-specific antibodies. A titer of greater than or equal to 1.4 indicated seropositivity.
Demographic and Time variables
👥Demographics
Age
Sex
⏳Time
Timepoint: Day after positive infection diagnosis when sample was taken
